Q3 Earnings Estimate for TLSI Issued By Roth Capital

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Equities research analysts at Roth Capital issued their Q3 2024 earnings per share (EPS) estimates for TriSalus Life Sciences in a research note issued on Monday, November 11th. Roth Capital analyst J. Wittes forecasts that the company will post earnings of ($0.35) per share for the quarter. Roth Capital has a "Strong-Buy" rating on the stock. The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($1.50) per share. Roth Capital also issued estimates for TriSalus Life Sciences' Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.47) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.40) EPS, FY2026 earnings at ($0.58) EPS and FY2027 earnings at ($0.19) EPS.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $7.36 million during the quarter.

Several other equities research analysts have also recently commented on TLSI. Roth Mkm began coverage on TriSalus Life Sciences in a research note on Monday. They issued a "buy" rating and a $11.00 target price on the stock. Oppenheimer assumed coverage on shares of TriSalus Life Sciences in a research report on Monday, September 16th. They issued an "outperform" rating and a $10.00 price objective on the stock. Northland Capmk raised shares of TriSalus Life Sciences to a "strong-buy" rating in a research report on Friday, October 25th. Finally, Northland Securities initiated coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They set an "outperform" rating and a $12.50 price target on the stock. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $12.25.

TriSalus Life Sciences Stock Up 0.9 %

Shares of TLSI stock traded up $0.04 on Wednesday, hitting $4.50. 15,074 shares of the stock were exchanged, compared to its average volume of 38,295. TriSalus Life Sciences has a fifty-two week low of $3.32 and a fifty-two week high of $10.42. The business has a 50-day moving average of $4.39 and a 200 day moving average of $5.86.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TLSI. Wolverine Asset Management LLC bought a new position in shares of TriSalus Life Sciences in the second quarter valued at about $240,000. Highbridge Capital Management LLC acquired a new position in TriSalus Life Sciences in the 2nd quarter valued at about $1,184,000. Finally, Duquesne Family Office LLC raised its holdings in TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company's stock valued at $2,357,000 after acquiring an additional 110,966 shares during the period. 2.58% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Mary T. Szela bought 7,520 shares of the business's stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the purchase, the chief executive officer now owns 377,382 shares of the company's stock, valued at approximately $1,962,386.40. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 32.80% of the company's stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.